The potential acquisition of Syqe Medical by Phillip Morris represents a significant strategic move for the tobacco giant, signaling its entry into the flourishing marijuana industry. With an initial investment of $130 million to support Syqe’s FDA approval process, followed by a possible $650 million acquisition, this deal can potentially make Syqe one of the largest cannabis companies globally. Moreover, Syqe’s innovative inhaler, utilizing raw cannabis inflorescence, could secure FDA approval, positioning the company as a trailblazer in the medical cannabis sector.
Slapwoods is announcing its first-ever official collaboration with DJ Screw, the late Houston legend whose…
It could be so easy to believe that cannabis culture is something that has been…
Modern cultivation techniques and spiritual practices collide with Pink Boost Goddess on our next Legendary…
Animal rescuers and advocacy groups say dogs living on Skid Row are suffering from neglect,…
This article originally appeared in High Times’ 50th Anniversary print issue. It is an excerpt…
How Montana built a legal cannabis market from a thin medical marijuana law, federal raids,…